TheraCryf Plc

TCF · AIM · Health Care · mcap £3.8m · 0.2p 2 open situations →

EV: £4.3m
EV / EBIT: –
Net cash: £471k
FCF yield: -55.7%
Revenue: –
Share price 1y: −17%
Insiders 12m: no deals
Next report: around 2 Dec

Beta Briefing, track record and signals & risks are not ready for TheraCryf Plc yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

20252026 Ox-1 Phase 1 approval in Australia Placing of 92% of the market value 1 director buying Placing of 91% of the market value 5 directors buying

Open · 2

Project milestones◷ in 66 days

Ox-1 Phase 1 approval in Australia

Preclinical complete; application being compiled

TheraCryf's lead orexin-1 antagonist for addiction has completed its preclinical package. On 19 Oct 2026 the company reported 28-day toxicology in two species with no adverse findings, at up to about 70 times the anticipated human dose. Avance Clinical was appointed on 2 Oct 2026 to support ethics review and notification. Application due November 2026, approvals targeted by 31 Dec 2026.

Toxicology: 28-day studies in two species; no adverse findings at any dose; top dose about 70x anticipated human dose (19 Oct 2026) 19 Oct 2026 ↗
Next milestone: Submit Australian first-in-human Phase 1 application in November 2026 19 Oct 2026 ↗
Approval target: Necessary approvals by 31 December 2026 19 Oct 2026 ↗
Partner: Avance Clinical appointed 2 October 2026 for ethics review and clinical trial notification 19 Oct 2026 ↗
Manufacturing and IP: Yields ahead of expectations; new IP with potential patent protection to 2046 19 Oct 2026 ↗
Webinar: Investor Meet Company webinar, 1.00 pm BST on 20 October 2026 19 Oct 2026 ↗

Next: Submit Australian Phase 1 trial application; approvals targeted by year end · 31 Dec 2026

19 Oct 2026 Preclinical complete; application being compiled

Open the full view – chart and every step →

Dilutive fundraise

Placing of 92% of the market value

completed

TheraCryf Plc is raising £4.25m gross by placing, 91.5% of its market value, at a 5% discount; the shares moved +0% on the day.

28 Sep 2026 completed · +0% on the day
20 Aug 2026 announced · +0% on the day

Open the full view – chart and every step →

Closed · 3

Insider conviction1 director buying £13k in 1 buy · 16 Oct 2025 – 14 Jan 2026 +14% Dilutive fundraisePlacing of 91% of the market value completed · 3 Jun 2025 – 3 Jul 2025 −31% Insider conviction5 directors buying £93k in 5 buys · 5 Apr 2024 – 4 Jul 2024 −6%

Company filings. Not investment advice.